Entrez un ou plusieurs mots-clés pour effectuer votre recherche

Cette page vous donne accès aux bases de données françaises concernant la Covid-19, recensées sur le Portail. Vous pouvez affiner votre recherche sur ces bases via le moteur de recherche.

Pour consulter d'autres ressources en lien avec la Covid-19, cliquez ici.

xml
XML

Exporter au format XML

Veuillez choisir le format :

XML
XML-DDI
pdf
PDF

Exporter au format PDF

Quelle version voulez-vous exporter ?

PDF complet
PDF simple
csv
CSV (Excel)

Exporter au format CSV

Quelles sections voulez-vous exporter ?

Métadonnées
Identification
Thématiques générales
Responsable(s) scientifique(s)
Collaborations
Financements
Gouvernance de la base de données
Contact(s) supplémentaire(s)
Type de base de données
Objectif de la base de données
Type de population
Dates
Taille de la base de données
Données
Modalités
Valorisation et accès
Accès
Tout sélectionner | Inverser la sélection | Aucune sélection
Exporter au format CSV

Covid-19 : 929 fiches

Tri des résultats :

Flash-RAS - Observational, retrospective study exploring RAS mutation tests practices in patients with metastatic colorectal cancer in 2014

Responsable(s) : ARTRU Pascal, MD, Gastroenterology, Hepatology and Gastrointestinal Oncology Department, Hôpital Jean Mermoz, lyon, France
DUCREUX Michel, Prof, Gastroenterology Unit, Gustave Roussy, Villejuif, France
LAURENT-PUIG Pierre, Prof, Biochemistry Department, HEGP, Paris, France
LIEVRE Astrid, MD, Gastroenterology Department, Pontchaillou University hospital, Rennes, France
MERLIN Jean Louis, Prof, Biopathology department, Institut de Cancérologie de Lorraine, Nancy, France
SABOURIN Jean-Christophe, Prof, Pathology department, CHU Ch.Nicolle, Rouen, France

Version 1
Voir
View
Résumé (apercu rapide)

925

Mise à jour : 25/10/2016

Flash-RAS - Observational, retrospective study exploring RAS mutation tests practices in patients with metastatic colorectal cancer in 2014

Responsable(s) : ARTRU Pascal, MD, Gastroenterology, Hepatology and Gastrointestinal Oncology Department, Hôpital Jean Mermoz, lyon, France
DUCREUX Michel, Prof, Gastroenterology Unit, Gustave Roussy, Villejuif, France
LAURENT-PUIG Pierre, Prof, Biochemistry Department, HEGP, Paris, France
LIEVRE Astrid, MD, Gastroenterology Department, Pontchaillou University hospital, Rennes, France
MERLIN Jean Louis, Prof, Biopathology department, Institut de Cancérologie de Lorraine, Nancy, France
SABOURIN Jean-Christophe, Prof, Pathology department, CHU Ch.Nicolle, Rouen, France

Objectif principal

To assess the RAS (KRAS and NRAS exons 2,3 and 4) mutation screening test request and realisation rates in patients with a recent diagnosis of metastatic colorectal cancer.

Secondary objectives:
- To describe changes in the KRAS (exon 2) mutation test request rate between 2011 and 2014;
- To describe the reasons for requesting/not requesting and performing/not performing these tests as a function of physician and patient profiles
- To describe and to analyse the impact of KRAS (exons 2,3 and 4) and NRAS (exons 2.3 and 4) results, the anatomopathology department availability to provide the tests, and the BRAF result, on therapeutic decision-making or changes in ongoing treatment;
- To describe and analyse clinical characteristics of patients and treatments planned and received as first-line therapy of metastatic disease;
- To describe the laboratory test method, the type of mutation request (if available) and the method and route by which the result was communicated to the physicians (result report);
- To describe and to analyse the time to receipt the KRAS and NRAS results, the process (who ordered the test and when) and the therapeutic approach chosen during this period

Critères d'inclusion

To obtain the best possible representativeness while limiting bias, the physician had to screen consecutive patients followed for metastatic colorectal cancer and who had to satisfy the following criteria:
- patients 18 years of age or older,
- patients with metastatic colorectal cancer histologically-confirmed after march 2014 (date the NRAS tests become available in French centers),
- patients seen by the physician between June 15th , 2014 and September 30th, 2014 who have already started first-line treatment, during that time interval, for mCRC
- patients in whom first-line therapy of metastatic disease had been already initiated between March 1st, 2014 and June 30th, 2014
- patients seen in a routine visit during the official 15-week screening period of the study

Mise à jour : 25/10/2016

Voir
View

AVANTAGE - Therapeutic strategies including Avastin as 1st line therapy in elderly patients suffering from advanced (IIIB/IV Stage) non-squamous non-small cell lung cancer, in routine clinical practice

Responsable(s) : Medical data center

Version 1
Voir
View
Résumé (apercu rapide)

926

Mise à jour : 18/01/2022

AVANTAGE - Therapeutic strategies including Avastin as 1st line therapy in elderly patients suffering from advanced (IIIB/IV Stage) non-squamous non-small cell lung cancer, in routine clinical practice

Responsable(s) : Medical data center

Objectif principal

In each cohort of patients defined by their age classification ([65; 70[ and >=70 years), outcome measures are as follows:
- Antineoplastic agents combined with bevacizumab as 1st line therapy
- Classes of antineoplastic agents combined with bevacizumab as 1st line therapy (platinum salt, taxanes,…)
- Supportive care (growth factors, analgesics).
to describe:
- Characteristics of advanced nsNSCLC patients treated with bevacizumab as first-line therapy, and their disease characteristics,
- Progression-Free Survival (PFS) and Overall Survival (OS),
- Evolution of patients’ quality of life over the treatment period with bevacizumab as first-line therapy,
- Safety of bevacizumab,
- Reasons for non-use of bevacizumab as first-line therapy in patients suffering from advanced nsNSCLC.

Critères d'inclusion

Inclusion criteria :
- Patient aged >= 65 years,
- Diagnosed with advanced nsNSCLC (stage IIIB or IV),
- For whom the physician has decided to initiate a treatment with bevacizumab combined with chemotherapy as 1st line therapy,
- Having received oral and written information about the study, and having signed a written consent form.

Mise à jour : 18/01/2022

Voir
View

- Epidemiology and treatment patterns in Soft Tissue Sarcoma (STS): a retrospective analysis on French expert centers databases

Responsable(s) : Pr BLAY Jean-Yves
Dr BUI NGUYEN Binh
Dr LE CESNE Axel
Pr COINDRE Jean- Michel
Dr DUCIMETIERE Françoise
Pr MATHOULIN-PELISSIER Simone

Version 1
Voir
View
Résumé (apercu rapide)

927

Mise à jour : 19/07/2016

- Epidemiology and treatment patterns in Soft Tissue Sarcoma (STS): a retrospective analysis on French expert centers databases

Responsable(s) : Pr BLAY Jean-Yves
Dr BUI NGUYEN Binh
Dr LE CESNE Axel
Pr COINDRE Jean- Michel
Dr DUCIMETIERE Françoise
Pr MATHOULIN-PELISSIER Simone

Objectif principal

To describe the treatment patterns of advanced (unresectable locally advanced or metastatic) STS (including viscus sarcoma) patients in France.

Secondary objectives:
- To describe STS (including viscus sarcoma) patients characteristics (sociodemographic data, type of sarcoma, histological subtype, tumor location, stage of the disease etc).
- To assess the STS (including viscus sarcoma) incidence in France
- To describe STS diagnosis (anatomopathology double review) and treatment history
- To describe the duration of the different treatments of STS disease

Critères d'inclusion

Patients with a diagnosis of STS, aged > 18 years-old, registered in the Conticabase/NetSarc/RRePS databases between January, 1st 2012 and December, 31st 2013 by a French expert center participating in the study between January, 1st 2012 and December, 31st 2013.

Mise à jour : 19/07/2016

Voir
View

Cancerology - Cancerology: real-world patient database in oncology & onco-hematology

Responsable(s) : Geneviève Bonnelye, Health division

Version 1
Voir
View
Résumé (apercu rapide)

928

Mise à jour : 10/09/2020

Cancerology - Cancerology: real-world patient database in oncology & onco-hematology

Responsable(s) : Geneviève Bonnelye, Health division

Objectif principal

To determine the epidemiology, patient & tumour characterstics, biomarkers, detailed treatment patterns, safety, and clinical outcomes across 25+ solid and non-solid tumours in France, Germany, Italy, Spain and the UK.

Critères d'inclusion

Patients currently receiving active anti-tumour drug treatment.

Mise à jour : 10/09/2020

Voir
View

miniNO-COVID - Exploratory multicenter observational study to assess the outcome of infants with perinatal SARS-COV-2 infection and its link with the NO pathway: the minipuberty hypothesis

Responsable(s) : STORME Laurent, Neonatal Intensive Care Unit of the CHU of Lille; FHU 1000 days for health
PREVOT Vincent, Laboratory of Development and Plasticity of the Neuroendocrine Brain; Lille Neuroscience & Cognition; FHU 1000 days for health

Version 1
Voir
View
Résumé (apercu rapide)

929

Mise à jour : 12/02/2021

miniNO-COVID - Exploratory multicenter observational study to assess the outcome of infants with perinatal SARS-COV-2 infection and its link with the NO pathway: the minipuberty hypothesis

Responsable(s) : STORME Laurent, Neonatal Intensive Care Unit of the CHU of Lille; FHU 1000 days for health
PREVOT Vincent, Laboratory of Development and Plasticity of the Neuroendocrine Brain; Lille Neuroscience & Cognition; FHU 1000 days for health

Objectif principal

To compare the follicle stimulating hormone (FSH) plasma concentrations measured at the postnatal age of 3 months between the three matched (on gestational age at birth, postnatal age and respiratory failure) newborn infants groups

Critères d'inclusion

o Newborn infants (24 to 41 weeks gestational age) or young infants (< 3 months) admitted at the maternity ward or at the Department of Neonatology at Jeanne de Flandre Hospital, CHU of Lille with perinatal COVID-19 infection defined by:
o Antenatal COVID-19 infection: pregnant women with positive PCR test at any time of the pregnancy;
o Post-natal COVID-19 infection: newborn or young infants (< 3 months) with positive PCR test in pharynx or stools as part of their treatment.
o Newborn infants (24 to 41 weeks gestational age) or young infants (< 3 months) admitted at the maternity ward or at the Department of Neonatology at Jeanne de Flandre Hospital, CHU of Lille for severe cardiorespiratory diseases requiring inhaled NO treatment.
o The control group without perinatal COVID-19 infection will be matched to thevtreatment group on gestational age at birth (± 2 weeks of gestation), on postnatal age (± 3 weeks) and respiratory failure.
o No inclusion in another ante- or post-natal trial;
o Written consents from both parents;

Mise à jour : 12/02/2021

Voir
View

Merci de patienter...

Partenaires - F.A.Q. - Contact - Plan du site - Mentions légales - Administration - PEF-HD - Mis à jour le 15 décembre 2020 - Version 4.10.05

Voir Modifier Créer ici